© 2019 Future Science Group

Unitec House, 2 Albert Place,

London, N3 1QB, UK

Email: info@future-science-group.com
Tel: +44 (0)20 8371 6090

  • LinkedIn - White Circle
  • Facebook - White Circle
  • Twitter - White Circle
  • YouTube - White Circle

News

07 February 2019
A novel approach to glioblastoma therapy proved safe and feasible for treatment

CNS Oncology is delighted to announce the publication of a second feasibility study for the Nativis Voyager® device for glioblastoma therapy.

 

The study demonstrates that the technology is safe and feasible as a standalone treatment, capable of delivering 2 separate therapeutic mimetics, referred to as cognates. The study group, an Australian-–American Collaboration led by Santosh Kesari of the John Wayne Cancer Institute and Pacific Neuroscience Institute (CA, USA), published their article entitled “A Feasibility Study of the Nativis Voyager® Device in Patients with Recurrent Glioblastoma (GBM) in Australia,” today in the open access journal CNS Oncology.

 

The Voyager device, which is a portable, non-invasive, battery-operated headband, delivers a precise oscillating magnetic field to the patient’s brain using ultra-low radiofrequency radiation (ulRFE®). The magnetic field is designed to mirror the electrostatic surface potential of solvated therapeutic molecules, thereby mimicking their therapeutic action. These electrostatic surface potentials are measured using a device developed specifically for this research to be the “most sensitive, highly-shielded, broadband, magnetic sensors produced anywhere in the world” stated Charles Cobbs, Chairperson of the Nativis Inc. (WA, USA) Scientific Advisory Board.

 

In addition to verifying the safety and feasibility of the device, the authors also demonstrate the ability of the Voyager to safely deliver disparate therapeutic cognates including cognate A1A, which is designed to mimic the action of paclitaxel, and A2HU, which aims to replicate the action of siRNA targeting CTLA4 and PD1.

 

This study paves the way for further research to expand the potential arsenal of therapeutic methods available for the treatment of glioblastoma.

 

“The technology has broad applicability in human medicine.  Currently, we are focusing on brain cancer which is a devastating disease, especially in children.  We are seeing encouraging early results when treating children diagnosed with diffuse midline glioma and diffuse intrinsic pontine glioma.  These children are generally diagnosed between 5 and 9 years of age, and median survival is 6–9 months post-diagnosis.  To make a difference in the life expectancy and quality of life of these young children is what I am most passionate and optimistic about.” explained co-author Donna Morgan Murray (Nativis Inc.).

 

Tristan Free, Editorial Assistant of CNS Oncology commented: “We are really excited to publish this paper documenting the beginning of a creative new technology for the treatment of a challenging condition. Insightful and forward-thinking articles like this are what CNS Oncology and Future Science Group are all about.”

Read more HERE.

 

 

About CNS Oncology

 

Launched in September 2012, CNS Oncology is a gold open access, biomedical journal from the Future Science Group. CNS Oncology addresses key issues and current understanding in the diagnosis, staging and treatment of disease by exploring the best patient-centered clinical research and presenting this information both directly, as clinical findings, and in practice-oriented formats of direct relevance in the clinic. CNS Oncology embraces the importance of publishing all good-quality research with the potential to further the progress of medical science. Both negative and early-phase research is considered. The journal also features review articles, editorials and perspectives, providing readers with a leading source of commentary and analysis.

 

About Future Science Group

 

Founded in 2001, Future Science Group (FSG) is a progressive publisher focused on breakthrough medical, biotechnological, and scientific research. FSG’s portfolio includes two imprints, Future Science and Future Medicine. In addition to this core publishing business, FSG develops specialist eCommunities. Key titles and sites include Bioanalysis Zone, Epigenomics, Nanomedicine and the award-winning Regenerative Medicine.

 

The aim of FSG is to service the advancement of clinical practice and drug research by enhancing the efficiency of communications among clinicians, researchers and decision-makers, and by providing innovative solutions to their information needs. This is achieved through a customer-centric approach, use of new technologies, products that deliver value-for-money and uncompromisingly high standards.